Quadratus lumborum pain: waves or injection? · Comparison study · 2017
How does shockwave compare with injections for lower-back muscle pain?
In this study, people who chose shockwave for long-lasting lower-back muscle pain went from about 7 to about 2 out of 10 a month after three sessions. Those who chose trigger-point injections went from about 7 to about 4. Day-to-day function improved in both groups, without a clear difference.
Pain fell more than with injections- inpatients with lower-back muscle pain
- 30
- sessions, three days apart
- 3
- month of follow-up
- 1
Good to know: People chose their own treatment.
Hong JO, Park JS, Jeon DG, et al. Ann Rehabil Med, 2017 · Read the paper ↗
How this study worked
What happened
Lower-back muscle pain
0–10 pain scale · start, after the third session and 1 month later
ShockwaveTrigger-point injections
Show the numbers
| Group | Start | After 3 sessions | 1 month later |
|---|---|---|---|
| Shockwave | 7.33 | 2.53 | 2.13 |
| Trigger-point injections | 6.64 | 3.71 | 3.86 |
The treatment
Shockwave
Shockwave, every 3 days, 3 times
- Sessions
- 3, every 3 days
- Pulses
- 2,000 per session · aimed at the tender muscle with ultrasound
- Strength
- 0.085–0.148mJ/mm²
- Numbing
- Not mentioned
- Device
- Dornier AR2
- Everyone also got
- Pain medicines, rest and therapeutic exercise
Compared with: Ultrasound-guided trigger-point injections, three times, three days apart, with the same medicines, rest and exercise
Settings are what each study used, not a prescription.
Who took part
30 hospital inpatients (17 men, 13 women; average age 53–55) with pain in a deep lower-back muscle (quadratus lumborum) for over three months.
Side effects
No serious side effects, such as unbearable pain or skin infection, in either group during the month of follow-up.
All the numbers and the full appraisal
The results, in numbers.
Patients hospitalized April 2015–June 2016 with isolated QL myofascial pain lasting over three months. Imaging/electrodiagnosis excluded other spinal causes. Mean ages 55.46 and 53.13 years; 17 men/13 women overall.
Source reports this participant group.
Source reports this participant group.
Pain intensity2 reported outcomes
Pain intensity
VAS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 7.33 (SD 0.82) | 2.53 (SD 1.06) |
| Trigger-point injection | 15 | 6.64 (SD 1.08) | 3.71 (SD 0.73) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Pain intensity
VAS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 7.33 (SD 0.82) | 2.13 (SD 0.92) |
| Trigger-point injection | 15 | 6.64 (SD 1.08) | 3.86 (SD 0.95) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Algometry2 reported outcomes
Pressure pain threshold
Algometry kg/cm²
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 3.42 (SD 0.71) | 4.76 (SD 0.56) |
| Trigger-point injection | 15 | 3.56 (SD 1.08) | 3.93 (SD 0.95) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Pressure pain threshold
Algometry kg/cm²
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 3.42 (SD 0.71) | 4.95 (SD 0.64) |
| Trigger-point injection | 15 | 3.56 (SD 1.08) | 3.89 (SD 0.9) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Oswestry disability2 reported outcomes
Oswestry disability
ODI points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 26.47 (SD 7.4) | 15.67 (SD 9.43) |
| Trigger-point injection | 15 | 31.71 (SD 8.97) | 20.79 (SD 10.37) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Oswestry disability
ODI points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 26.47 (SD 7.4) | 15.53 (SD 9.5) |
| Trigger-point injection | 15 | 31.71 (SD 8.97) | 20.64 (SD 10.28) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
RM (source-labelled Roles and Maudsley)2 reported outcomes
RM: source instrument identity uncertain
RM (source-labelled Roles and Maudsley) reported points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 16.2 (SD 4.28) | 9.67 (SD 4.61) |
| Trigger-point injection | 15 | 17.29 (SD 5) | 11.07 (SD 5.41) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Instrument identity is unresolved: the source labels this Roles and Maudsley, but baseline values 16–17 are incompatible with its categorical method description. These numbers are not a verified validated scale; do not relabel as Roland-Morris. Mean±SD transcribed as printed.
RM: source instrument identity uncertain
RM (source-labelled Roles and Maudsley) reported points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 16.2 (SD 4.28) | 9.2 (SD 4.18) |
| Trigger-point injection | 15 | 17.29 (SD 5) | 12.71 (SD 4.36) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Instrument identity is unresolved: the source labels this Roles and Maudsley, but baseline values 16–17 are incompatible with its categorical method description. These numbers are not a verified validated scale; do not relabel as Roland-Morris. Mean±SD transcribed as printed.
Quebec Back Pain Disability Scale2 reported outcomes
Quebec disability
Quebec Back Pain Disability Scale points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 48.13 (SD 19.18) | 24.4 (SD 12.3) |
| Trigger-point injection | 15 | 53.57 (SD 16.44) | 34.43 (SD 19.1) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Quebec disability
Quebec Back Pain Disability Scale points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| ESWT | 15 | 48.13 (SD 19.18) | 23.3 (SD 10.22) |
| Trigger-point injection | 15 | 53.57 (SD 16.44) | 33.86 (SD 17.82) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Comparative changes1 reported outcome
Comparative changes
Qualitative finding
At one month VAS was 2.13±0.92 with ESWT versus 3.86±0.95 with injection; pressure threshold 4.95±0.64 versus 3.89±0.90 kg/cm². Figure 1 reports comparative change p=.001 for both pain outcomes. ODI, RM and Quebec differences were not significant (p=.160,.155,.089). Pain associations favored ESWT; causal superiority is not established by patient-selected allocation.
Analysis details and source
Qualitative extraction preserves the source scope.
How treatment was delivered
Dornier AR2, ultrasound-guided to tender QL belly, 2,000 shocks at 0.085–0.148 mJ/mm², three sessions at three-day intervals. Prone positioning and ultrasonography were used to locate the muscle.
Ultrasound-guided trigger-point injection three times at three-day intervals. Injectate and volume are not reported. Both groups received analgesics, rest and therapeutic exercise.
No serious adverse events such as intolerable pain or subcutaneous infection were reported in either group. This small one-month observation cannot exclude uncommon or delayed events.
Preference-based allocation, small inpatient sample, no sham and short follow-up. The RM outcome is named Roles/Maudsley, but Table 1 scores around 16–17 conflict with the categorical method description; it must not be relabelled Roland-Morris without correction. Supported by Je Won Research Foundation; no relevant conflicts declared.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Preference-based allocation, small inpatient sample, no sham and short follow-up. The RM outcome is named Roles/Maudsley, but Table 1 scores around 16–17 conflict with the categorical method description; it must not be relabelled Roland-Morris without correction. Supported by Je Won Research Foundation; no relevant conflicts declared.
Source-linked critical reading
nonrandom comparative
Technical source record
Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. The article cites no supplementary material.
People choosing shockwaves reported greater short-term pain improvement, but function did not clearly improve more than with injection. The study cannot show which treatment caused the difference.
In chronic quadratus-lumborum myofascial pain, how did ESWT compare with trigger-point injection?
Retrospective nonrandomized comparison: patients selected treatment after explanation. Thirty hospitalized patients were divided 15/15; preference and co-interventions can confound the apparent difference.
Patients hospitalized April 2015–June 2016 with isolated QL myofascial pain lasting over three months. Imaging/electrodiagnosis excluded other spinal causes. Mean ages 55.46 and 53.13 years; 17 men/13 women overall.
Dornier AR2, ultrasound-guided to tender QL belly, 2,000 shocks at 0.085–0.148 mJ/mm², three sessions at three-day intervals. Prone positioning and ultrasonography were used to locate the muscle.
Ultrasound-guided trigger-point injection three times at three-day intervals. Injectate and volume are not reported. Both groups received analgesics, rest and therapeutic exercise.
Primary pain outcomes were VAS 0–10 and pressure-pain threshold. Secondary outcomes were ODI, a measure labelled RM and Quebec disability score, at baseline, immediately after treatment and one month later.
At one month VAS was 2.13±0.92 with ESWT versus 3.86±0.95 with injection; pressure threshold 4.95±0.64 versus 3.89±0.90 kg/cm². Figure 1 reports comparative change p=.001 for both pain outcomes. ODI, RM and Quebec differences were not significant (p=.160,.155,.089). Pain associations favored ESWT; causal superiority is not established by patient-selected allocation.
No serious adverse events such as intolerable pain or subcutaneous infection were reported in either group. This small one-month observation cannot exclude uncommon or delayed events.
Preference-based allocation, small inpatient sample, no sham and short follow-up. The RM outcome is named Roles/Maudsley, but Table 1 scores around 16–17 conflict with the categorical method description; it must not be relabelled Roland-Morris without correction. Supported by Je Won Research Foundation; no relevant conflicts declared.
Results apply to selected inpatients with isolated QL pain receiving shared conservative care. Disability benefit over injection was not demonstrated, and longer-term outpatient outcomes remain unknown.
Randomize treatment, specify injectate and shared care, resolve RM instrument identity, blind assessors and report prespecified pain/disability contrasts with intervals and longer follow-up.
Read the original article.
Extracorporeal Shock Wave Therapy Versus Trigger Point Injection in the Treatment of Myofascial Pain Syndrome in the Quadratus Lumborum
Hong JO, Park JS, Jeon DG, Yoon WH, Park JH. · Ann Rehabil Med · 2017
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →